share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Harris Matthew Scott

SEC announcement ·  Feb 2 07:02
Summary by Futu AI
Matthew Scott Harris, Chief Medical Officer of Altimmune, Inc., completed a series of transactions involving the company's common stock over the course of January 30 and 31, 2024. On January 30, Harris exercised options to acquire 9,275 shares at no cost and subsequently disposed of 2,709 shares at a price of $9.80 per share to cover exercise prices or tax liabilities, resulting in a total market value of $26,548.20 for the disposed shares. The following day, Harris acquired an additional 3,257 shares at $2.69 per share through a grant or award. After these transactions, Harris's direct holdings in Altimmune common stock increased to a total of 43,825 shares.
Matthew Scott Harris, Chief Medical Officer of Altimmune, Inc., completed a series of transactions involving the company's common stock over the course of January 30 and 31, 2024. On January 30, Harris exercised options to acquire 9,275 shares at no cost and subsequently disposed of 2,709 shares at a price of $9.80 per share to cover exercise prices or tax liabilities, resulting in a total market value of $26,548.20 for the disposed shares. The following day, Harris acquired an additional 3,257 shares at $2.69 per share through a grant or award. After these transactions, Harris's direct holdings in Altimmune common stock increased to a total of 43,825 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.